• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?

    1/7/25 4:15:00 PM ET
    $LKQ
    $ZTS
    Motor Vehicles
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LKQ alert in real time by email

    TROY, Mich., Jan. 7, 2025 /PRNewswire/ -- Zoetis's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Zoetis (NYSE:ZTS) as worthy of further study and has named Zoetis its "Stock to Study" for the March 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Zoetis's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors, at:  https://ssg.betterinvesting.org/trial/ssgplus/?ticker=ZTS.

    A full report on Zoetis will appear in the March 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of LKQ Corp. (NASDAQ:LKQ) which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/is-zoetis-inc-nyse-zts-overvalued-or-is-it-worth-buying-now-302344973.html

    SOURCE National Association of Investors/BetterInvesting

    Get the next $LKQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LKQ
    $ZTS

    CompanyDatePrice TargetRatingAnalyst
    LKQ Corporation
    $LKQ
    12/10/2025$39.00Overweight
    Stephens
    Zoetis Inc.
    $ZTS
    12/9/2025$136.00Equal Weight
    Barclays
    Zoetis Inc.
    $ZTS
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    LKQ Corporation
    $LKQ
    11/12/2025$33.00Equal Weight
    Barclays
    Zoetis Inc.
    $ZTS
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    Zoetis Inc.
    $ZTS
    6/18/2025$160.00Buy → Hold
    Stifel
    Zoetis Inc.
    $ZTS
    12/2/2024$215.00Outperform
    Leerink Partners
    Zoetis Inc.
    $ZTS
    7/25/2024$220.00Buy
    BTIG Research
    More analyst ratings

    $LKQ
    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on LKQ with a new price target

    Stephens initiated coverage of LKQ with a rating of Overweight and set a new price target of $39.00

    12/10/25 8:28:13 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Barclays initiated coverage on Zoetis with a new price target

    Barclays initiated coverage of Zoetis with a rating of Equal Weight and set a new price target of $136.00

    12/9/25 8:55:22 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Zoetis

    KeyBanc Capital Markets initiated coverage of Zoetis with a rating of Sector Weight

    11/21/25 8:12:07 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --

    12/11/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

    Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well tolerated, including by cats identified with kidney disease at IRIS stage 1, 2 or 31. Portela is also approved in the European Union (EU), and Zoetis anticipates making Portela commercially available in Canada and the EU in 2026. "H

    12/5/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Urbain Xavier bought $481,756 worth of shares (15,000 units at $32.12), increasing direct ownership by 80% to 33,669 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    8/29/25 1:25:47 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Director Clarke Andrew C bought $159,773 worth of shares (5,000 units at $31.95), increasing direct ownership by 31% to 21,172 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    8/27/25 3:51:39 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    President and CEO Jude Justin L bought $178,574 worth of shares (5,669 units at $31.50), increasing direct ownership by 2% to 286,446 units (SEC Form 4)

    4 - LKQ CORP (0001065696) (Issuer)

    8/27/25 3:51:23 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    $LKQ
    $ZTS
    SEC Filings

    View All

    Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    12/11/25 4:17:25 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LKQ Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - LKQ CORP (0001065696) (Filer)

    12/4/25 7:12:47 AM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    Zoetis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    12/2/25 8:00:17 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Zoetis Inc.

    3 - Zoetis Inc. (0001555280) (Issuer)

    12/2/25 4:28:48 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tilenius Stephanie

    4 - Zoetis Inc. (0001555280) (Issuer)

    12/2/25 4:28:43 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Vice President Fuller Julie

    4 - Zoetis Inc. (0001555280) (Issuer)

    10/14/25 4:27:52 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LKQ
    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LKQ Corporation

    SC 13G - LKQ CORP (0001065696) (Subject)

    11/7/24 4:30:56 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by LKQ Corporation (Amendment)

    SC 13G/A - LKQ CORP (0001065696) (Subject)

    2/13/24 5:08:05 PM ET
    $LKQ
    Motor Vehicles
    Consumer Discretionary

    $LKQ
    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --

    12/11/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

    Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. "The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives

    12/2/25 7:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Third Quarter 2025 Results

    Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income

    11/4/25 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care